The present invention discloses compounds of the formula
##STR1##
any of its enantiomers or any mixture thereof, isotopes thereof or a pharmaceutically
acceptable salt thereof;
wherein
- n is 1, 2 or 3;
- m is 0, 1 or 2;
- R represents hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, or aralkyl; and
R1 represents aminophenyl; nitrophenyl; hydroxyphenyl, alkoxyphenyl;
a monocyclic 5 to 6 membered heterocyclic group which may be substituted one or
more times with substituents selected from the group consisting of alkyl, cycloalkyl,
cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, alkynoxy,
methylenedioxy, halogen, CF3, OCF3, CN, amino, nitro, COOR3,
CONR2R3, NHCO2R2,
NHCOR2, OCONR2R3;
wherein R2 and R3 independently represents hydrogen
or alkyl;
- aryl optionally substituted one or more times with alkyl, cycloalkyl,
cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy,
halogen, CF3, OCF3, CN, amino and nitro;
- X-alkyl-Y-alkyl wherein X and Y independently represents O,
S, NH, N-alkyl or Se; and alkyl is optionally substituted with alkoxy or thioalkoxy;
- X-(alkyl)o-aryl wherein o is 0 or 1 and X represents
O, S, NH, N-alkyl or Se; optionally substituted one or more times with alkyl, cycloalkyl,
cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy,
halogen, CF3, OCF3, CN, amino and nitro;
- X-(alkyl)o-Z wherein o is 0 or 1 and X represents
O, S, NH, N-alkyl or Se and Z represents a 5- or 6-membered monocyclic heterocyclic
group; optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl
alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen,
CF3, OCF3, CN, amino and nitro;
- a monocyclic 5 to 6 membered heterocyclic group optionally substituted
one or more times with alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy,
cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF3, OCF3,
CN, amino and nitro; or
or R1 represents a bicyclic heterocyclic group, composed of a 5 to
6 membered monocyclic heterocyclic group fused to a benzene ring, and which may
be substituted one or more times with substituents selected from the group consisting
of alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, alkoxy-alkoxy,
cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF3, OCF3,
CN, amino, nitro, aryl optionally substituted one or more times with alkyl, cycloalkyl,
cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy,
halogen, CF3, OCF3, CN, amino and nitro; and a monocyclic
5 to 6 membered heterocyclic group optionally substituted one or more times with
alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy,
alkynoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro;
The compounds of the invention are useful as nicotinic ACh receptor ligands.
|
|
|